Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, completed the previously announced tender offer by Catalent Boston, Inc. (“Merger Sub”), a subsidiary of Catalent Pharma Solutions, Inc. (“Parent”), Catalent’s operating subsidiary, for all of the outstanding shares of common stock of Juniper Pharmaceuticals, Inc. at a…
Catalent Signs Agreement To Acquire Juniper Pharmaceuticals
Catalent, Inc. today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc., including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing drug development and manufacturing capabilities in the U.S. and Europe, the acquisition of Juniper will expand and strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing,…
Catalent Reports Fiscal 2Q Revenue Up 25 Percent
Catalent, Inc. Reports Second Quarter Fiscal 2018 Results Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced financial results for the second quarter of fiscal 2018, which ended December 31, 2017. Second quarter 2018 revenue of $606.3 million increased 25 percent as reported…
